Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesothelin-targeted autologous CAR-T cells
- Development stage
- Unknown
- Lead developer
- Shanghai Sixth People’s Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Mesothelin-targeted autologous CAR-T cells are an investigational cellular immunotherapy consisting of autologous T cells genetically engineered, typically via lentiviral transduction, to express a chimeric antigen receptor (CAR) targeting mesothelin (MSLN). Mesothelin is a cell-surface glycoprotein that is highly overexpressed in various malignant solid tumors, including mesothelioma, pancreatic cancer, ovarian cancer, and lung adenocarcinoma, while showing limited expression in normal tissues. Upon infusion, these CAR-T cells specifically bind to mesothelin-expressing tumor cells, leading to T-cell activation, proliferation, and targeted cytotoxicity. This therapy is being evaluated in clinical trials, such as those conducted by the Shanghai Jiao Tong University Affiliated Sixth People's Hospital, for the treatment of advanced mesothelin-positive malignant solid tumors.
- Other names
- meso-CAR-Tmeso-CAR-T cellsmesothelin-targeted CAR-T cellsmesothelin-targeted autologous chimeric antigen receptor T cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on mesothelin-targeted autologous CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesothelin-targeted autologous CAR-T cells.